Chapter 5: Psychopharmacology

5.7: References

Adapted from

Barron, S. (2023). Psychopharmacology. In R. Biswas-Diener & E. Diener (Eds), Noba textbook series: Psychology. Champaign, IL: DEF publishers. Retrieved from

“The Brain from Top to Bottom” (n.d.). Retrieved on June 1, 2023 from


Bailey D. G., Dresser G., & Arnold J. M. (2013). Grapefruit-medication interactions: forbidden fruit or avoidable consequences? Canadian Medical Association Journal, 185, 309–316.

Brown, M. J., & Mezuk, B. (2012). Brains, bones, and aging: psychotropic medications and bone health among older adults. Current Osteoporosis Reports, 10, 303–311.

Centers for Disease Control and Prevention (CDC) (2011) Prevalence of autism spectrum disorders – autism and developmental disabilities monitoring network, 14 sites, United States, 2008. Morbidity and Mortality Weekly Report 61(SS03) 1–19.

Centers for Disease Control and Prevention (CDC) (2013) Mental health surveillance among children – United States, 2005—2011. Morbidity and Mortality Weekly Report 62 Suppl, 1-35.

Centers for Disease Control and Prevention (CDC) (2023). Data & Statistics on Autism Spectrum Disorder.

Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., … & Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946-1949.

Hilmer, N., & Gnjidict, D. (2008). The effects of polypharmacy in older adults. Clinical Pharmacology & Therapeutics, 85, 86–88.

Ioannidis, J. P. A. (2008). Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philosophy, Ethics, and Humanities in Medicine, 3,14.

Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Archives of General Psychiatry, 62, 617–627.

Moreno, C., Laje, G., Blanco, C., Jiang, H., Schmidt, A. B., & Olfson, M., (2007). National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Archives of General Psychiatry, 64(9), 1032–1039.

Pollock, B. G., Forsyth, C. E., & Bies, R. R. (2008). The critical role of clinical pharmacology in geriatric psychopharmacology. Clinical Pharmacology & Therapeutics, 85, 89–93.

Rohsenow, D. J., Niaura, R. S., Childress, A. R., Abrams, D. B., & Monti, P. M. (1990). Cue reactivity in addictive behaviors: Theoretical and treatment implications. International Journal of Addiction, 25, 957–993.

Santomauro, D. F., Herrera, A. M. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., … & Ferrari, A. J. (2021). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. The Lancet, 398(10312), 1700-1712.

Schwartz, J. B., & Abernethy, D. R. (2008). Aging and medications: Past, present, future. Clinical Pharmacology & Therapeutics, 85, 3–10.

“The Brain from Top to Bottom” (n.d.). Retrieved on June 1, 2023 from

World Health Organization (2004). Promoting mental health: concepts, emerging evidence, practice (Summary Report). Geneva, Switzerland: Author. Retrieved from;

Zhou, S. F. (2009). Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clinical Pharmacokinetics, 48, 761–804.


Icon for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

Biological Psychology Copyright © 2024 by Michael J. Hove and Steven A. Martinez is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, except where otherwise noted.

Share This Book